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Summary Although cellular drug resistance is considered to be an important cause of the poor prognosis of
children with relapsed acute lymphoblastic leukaemia (ALL), the knowledge of drug resistance in these
patients is very limited. Different aspects of drug resistance were studied in 17 children with relapsed ALL.
The in vitro sensitivity profile was determined using the MTT assay. Cells from relapsed children were
significantly more resistant to 6-thioguanine, prednisolone, cytosine arabinoside, daunorubicin (DNR),
mustine-HCI and mafosfamide but not to L-asparaginase and vincristine (VCR) than cells from 41 children
with ALL at initial diagnosis. Some relapsed patients showed a general drug resistance while others were
resistant to only 1-3 drugs. The relevance of the multidrug resistance (MDR) model was analysed: In all
DNR- and VCR resistant cases a co-resistance to drugs not involved in the MDR model was found.
P-glycoprotein was not detected in any of 28 untreated and 14 relapsed samples tested. VCR- and DNR
accumulation in the most resistant cells were not lower than in sensitive cells. Resistance modifiers did not
potentiate the cytotoxicity of VCR and DNR. We conclude that resistance to anthracyclines and vinca-
alkaloids in childhood relapsed ALL is not due to P-glycoprotein mediated MDR. Different types of drug
resistance varying from a resistance to only one drug to a general chemoresistance, can be detected in children
with relapsed ALL. VCR and L-asparaginase seemed to be only infrequently involved in drug resistance.
Knowledge of drug resistance might lead to more effective and less toxic therapies for children with relapsed
ALL.
The use of combination chemotherapy in children with acute
lymphoblastic leukaemia (ALL) presently results in a com-
plete remission rate of more than 95%. With the best cur-
rently available treatment, about two thirds of these children
will remain in continuous complete remission and can there-
fore be considered cured. Patients suffering from a relapse
however have a cure rate which is much lower. One of the
main causes of this poor prognosis is probably a resistance of
the leukaemic cells to a number of drugs used for treatment
(Rivera et al., 1989).
At present the knowledge of drug resistance in childhood
ALL is very limited. It is unknown how often, when, and for
which drugs resistance is occurring. Currently, much atten-
tion is given to the multidrug resistance (MDR) pheno-
menon: a resistance to vinca-alkaloids and anthracyclines,
mediated by the drug efflux pump P-glycoprotein (P-gp), that
can at least be partially overcome by so-called resistance
modifiers. The clinical significance of MDR in childhood
ALL is still unknown. Recently, we and others adapted and
improved assays to detect drug resistance of leukaemic cells
obtained from patients (Weisenthal et al., 1986; Bird et al.,
1986; Hongo et al., 1987; Pieters et al., 1988, 1989; Campling
et al., 1988; Twentyman et al., 1989) showing good correla-
tions between in vitro results and clinical response to chemo-
therapy (Tidefelt et al., 1989; Sargent & Taylor, 1989; Santini
et al., 1989; Veerman & Pieters, 1990; Bosanquet et al., 1991;
Pieters et al., 1990, 1991). Because of the development of
these short-term assays it has recently become possible to
study drug resistance of patients with ALL. In the present
study we assessed the resistance profiles of children with
relapsed ALL and the clinical relevance of the MDR model
in these patients.
Materials and methods
Drug sensitivity assay
Leukaemic cells were obtained from bone marrow and
peripheral blood samples taken for routine diagnostic proce-
dures. Preparation of mononuclear cell suspensions and drug
solutions have been described earlier (Pieters et al., 1990). In
most cases, cells were used after cryopreservation. Patients
with B-cell ALL characterised by the expression of surface
immunoglobulins, were excluded from the study. Part of the
samples were used in an earlier study (Pieters et al., 1990).
Drug sensitivity was determined with the 4-day MTT assay
as described earlier (Pieters et al., 1990). Briefly, 80fd cell
suspension was dispensed into 96-well microtitre plates con-
taining 20 jil of a drug. Stocks of microculture plates contain-
ing drugs in 20 jlI/well were prepared every 2 months and
stored at - 20°C. We have previously shown that the drugs
stored in this manner are stable for at least 4 months (Pie-
ters et al., 1990). The percentage of malignant cells was
90.4 ± 8.9% (range 65-100) and was not different between
samples from untreated and relapsed ALL patients. Bone
marrow and peripheral blood cells do not differ in drug
sensitivity (Kaspers et al., 1991). Six concentrations of each
drug were tested in duplicate. The drugs and range of end
concentrations and dilution factors were: 6-thioguanine (6-
TG, 1.56-50 jg ml-', 2-fold dilutions); vincristine (VCR,
0.05-50jIgml', 4-fold); prednisolone (Pred, 0.08-250jig
ml-', 5-fold); daunorubicin (DNR, 0.002-2.0jigmI 1, 4-
fold); mafosfamide (Maf, 0.10-100 jigml-', 4-fold); cytosine
arabinoside (Ara-C, 0.0024-2.5 jig ml-', 4-fold); mustine
HCI (Must, 0.16-500 ig ml- ', 5-fold); L-asparaginase (L-
Asp, 0.003-10 IU ml' 5-fold). Untreated control cells were
set up in 6-fold. Plates were incubated in a humidified
incubator in 5% CO2 for 4 days at 37°C. Then 10 jil MTT
solution was added and after shaking for 1 min the plate was
incubated for 6 h. The tetrazolium salt MTT is reduced to a
coloured formazan by living, but not by dead cells. For-
mazan crystals were dissolved with 100 jl of acid isop-
ropanol. The optical density (OD) of the wells was measured
with a microplate reader (Titertek Multiskan MCC 340) at
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540 nm. The OD is linearily related to cell number. The OD
at day 4 was not significantly different between untreated and
relapsed samples. Elsewhere we showed that there was no
relation between control OD and resistance to the drugs
tested (Pieters et al., 1990). Leukaemic cell survival (LCS)
was calculated by the equation:
LCS = (OD treated well/mean OD control wells) x 100%.
LC50 was derived by calculating the point where the dose-
response curve crosses 50% LCS.
MDR parameters
The effects of the resistance modifiers cyclosporine A (San-
dimmuneR; CsA; 2 ttg ml-'), verapamil (Vp; 5 jg ml-') and
lidocaine (40 jg ml-') upon leukaemic cell kill by VCR,
DNR, and 6-TG or 6-mercaptopurine were tested using the
MTT assay. The purine analogues, not belonging to the
drugs involved in MDR, were incorporated in this part of the
study to detect a possible non-specific effect of resistance
modifiers. The concentrations of the resistance modifiers were
derived from dose response curves of a very wide range of
concentrations tested in five ALL samples. The final concent-
rations were chosen for further studies because these were
not so high that already all ALL cells were killed which
would make further combining experiments with cytostatic
drugs useless. On the other hand we did not want to use too
low concentrations which could have resulted in the pos-
sibility of missing synergistic effects.
Different columns of microplates were filled with 40IlI of
drug, resistance modifier or the combination of these two in
duplicate and stored at - 20°C until use. After thawing, 60 .tl
of cell suspension was added. Drugs were tested in the fol-
lowing concentrations: VCR 0.05, 0.78 and 12.5 ig ml1';
DNR 0.008, 0.125 and 2.0OgIml'; thiopurines 1.95, 7.81
and 31.25 ;g ml-'. The effect of modifier and drug (e.g.
DNR) was defined as synergistic if the cell kill by the com-
bination of both was more than the product of the cell kill
by modifier and drug tested separately. For instance, if Vp
results in 80% LCS and DNR in 50% LCS, the combination
of both must result in a LCS <40% to be defined as
synergistic. The correction formula for the LCS is:
Corrected LCS = (LCS with [modifier + DNR] x 100%)/
(LCS with modifier alone)
For instance, if Vp results in 80% LCS, DNR in 50% LCS
and the combination of both in 40% LCS, then the corrected
LCS is 50%. This means that in this example there is only an
additional effect and no synergistic effect because the cell kill
by DNR alone was also 50%.
Accumulation studies were carried out as described else-
where (Broxterman et al., 1987, 1988). Briefly, the cells were
incubated during 60min at 37°C with '4C-daunorubicin or
3H-vincristine in medium with 10% FCS and 20 mM Hepes,
pH 7.45, with or without resistance modifiers as indicated.
Cells were washed twice with ice-cold phosphate buffer saline
and cell-associated radioactivity was quantitated by liquid
scintillation counting. Cell area measurements were per-
formed with a digitising interactive video overlay system
(PRODIT, Promis, Almere, The Netherlands) at a final
magnification of approximately 3000 x. Cells were selected
up to a sample size of 100 according to the 'zone method'
(van Diest et al., 1989). P-glycoprotein staining of cytospun
leukaemic cells was done with the monoclonal antibodies
C219 and JSB-l using the Histostain-SP kit as described
previously (Broxterman et al., 1989). Cells from the cell line
8226/Dox4, obtained from Dr W.S. Dalton (Arizona Cancer
Center), showing a low multidrug resistance associated with
P-gp expression were simultaneously stained and used as a
weakly positive control (Dalton et al., 1989).
Statistics
The Wilcoxon matched-pairs signed-ranks test and the
Mann-Whitney U test (MWU) were used for two-tailed tes-
ting at a level of significance of 0.05.
Results
Patient characteristics of the relapsed patients are shown in
Table I. Drug sensitivity profiles were evaluable in 41 un-
treated ALL patients at initial diagnosis and in 11 patients
with relapsed ALL. Relapsed patients were significantly more
resistant to 6-TG, Pred, DNR, Ara-C, Must and Maf but not
to VCR and L-Asp than untreated patients (Table II). The
LC50 values for DNR, VCR, Pred and L-Asp are shown in
Figure 1.
Since for some drugs the LC50 values of untreated patients
show a non-parametric distribution (see e.g. the Pred data in
Figure 1) the mean and standard deviations are less adequate
parameters to describe these data. This problem can be cir-
cumvented by using percentiles. For example, a sample in the
90th percentile (P90) means that this sample is more resistant
than 90% of all samples tested. The P50 is identical to the
median. The PlO, P50 and P90 of untreated ALL samples are
shown in Figure 2. Using the P90 of untreated patients as
cut-offpoint ofresistance, the resistance profiles ofindividual
relapsed patients are presented in Figure 2. Some patients
(R3b, R7, R9) are resistant to almost all drugs tested while
others (RI, R2, R8, RIO, R12, R15, R16, R17) are resistant
to only 1-3 drugs.
In two relapsed cases (R3b and R7) the resistance profiles
at time of relapse can be compared with those at time of
initial diagnosis (Table III). In case 3b the LCm values at
initial diagnosis were already higher than the P90 for VCR,
Ara-C, Must, Maf and close to this cut-off level for 6-TG
and Pred. Cells 'acquired' resistance to DNR and to a lesser
extent to 6-TG, Pred and L-Asp. In case R7 cells were
initially sensitive to all drugs, but at time of relapse the cells
were sensitive to L-Asp only when using the P90 as cut-off
point. A clear decrease in sensitivity was seen for Ara-C and,
like in case R3b, for DNR, Pred, and L-Asp although in
both cases the LC^, value of L-Asp was below the (arbit-
rarely chosen) P90.
Table I Characteristics of relapsed ALL patients
Patient No. Comments
RI 2nd BM relapse ofT-ALL
R2 1st BM relapse of T-ALL
R3a 3rd BM testis and lymph node relapse ofcALL
R3b 4th BM relapse 2 yr after 3rd relapse
R4 3rd BM relapse of cALL
R5 1st BM relapse of cALL
R6 2nd BM relapse ofcALL
R7 1st BM relapse of T-ALL
R8 3rd BM and CNS relapse of cALL
R9 1st BM relapse ofmixed lineage ALL/ANLL
RIO 2nd BM relapse of cALL
RI1 1st BM relapse ofcALL
R12 6th BM relapse of cALL
R13 4th BM and CNS relapse of cALL
R14 1st CNS relapse ofT-ALL
R15 1st BM and CNS relapse ofcALL
R16 3rd BM relapse of T-ALL
R17 2nd BM relapse ofT-LL
BM= bone marrow; CNS = central nervous system.
Table II LC50 values of cells from newly diagnosed, initial patients
(n = 41) and relapsed patients (n = 11) given intLgml1' with exception
ofvalues forL-AspwhichisgiveninIU ml-'. Differencesbetweenthese
two groups are tested with the Mann-Whitney U test
Median Median Range Range
Drug initial relapse initial relapse P
6-TG 4.4 11.9 1.6-14.9 4.7-16.1 .0004
AraC 0.131 0.460 0.016-1.188 0.114-2.500 .0016
Asp 0.177 0.500 0.003-10.000 0.033-8.590 .0906
DNR 0.115 0.363 0.002-0.895 0.075-0.910 .0299
Maf 4.4 24.0 0.5-50.0 13.1-54.4 .0022
Must 22.2 90.3 1.1 -87.0 16.2-198.4 .0016
Pred 0.3 250.0 0.1-250.0 0.2-250.0 .0019
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Figure 1 LC50 values of cells from untreated and relapsed ALL
patients, given in ig ml' for DNR, VCR and Pred and in
IUml-' for 1-Asp.
In order to study whether classic MDR plays a role in
clinical resistance in ALL patients we studied several aspects
of the MDR model:
(a) Cross resistance to vinca-alkaloids and anthracyclines
As shown above the group of relapsed patients was
significantly more resistant to DNR but not to VCR than the
group ofuntreated ALL patients. Looking at individual cases
(Figure 2), a resistance to both VCR and DNR was found in
two patients (R3b and R7) while in two others (R9, R16)
cells were resistant to DNR but not to VCR. In all four cases
however this was associated with resistance to other drugs
which are not involved in the MDR model.
(b) P-gp expression
P-gp staining was performed on cells from 28 untreated and
14 relapsed ALL samples (RI -3b, R7, R9-17). Cells from
the positive control cell line 8226/Dox4, stained simultan-
eously, were clearly P-gp positive. All 42 cases, including the
four cases who showed an in vitro resistance to DNR and
VCR, were P-gp negative.
(c) Resistance modifiers
Results of testing resistance modifiers were evaluable in 12
untreated and eight relapsed samples. CsA alone decreased
LCS to 88 ± 38% (mean ± s.d.), Vp to 96 ± 12% and lido-
caine to 96 ± 13%. In two samples CsA increased LCS
dramatically to 143% and 160% respectively. In the first of
these cases, CsA was tested in concentrations ranging from
0.06 to 2 igml-'. It appeared that the increased LCS was
dose-dependent reaching a maximum of 158% at 0.5 pgml'
CsA followed by a decline to 143% at 2jugml1'.
Figure 3 shows the ALL cell kill by combinations of
resistance modifiers and cytostatic drugs corrected for the
effect of the resistance modifiers alone. Addition of modifiers
did not lead to a significantly increased cell kill by VCR,
DNR, and thiopurines. In none of the combinations the
influence of resistance modifiers upon cell kill by cytostatic
drugs was significantly different between relapsed and un-
treated patients.
In three relapsed and seven untreated patients we studied
the accumulation of DNR and VCR with and without Vp
(Table IV). Vp did not enhance DNR accumulation (mean
96.4%, range 83-108%) while VCR accumulation was in-
creased to a mean of 125% (range 81-168%). We also found
that 16pJM Vp increases the VCR accumulation of normal
peripheral blood lymphocytes to 120-130% (data not
shown). Cells from case R3b which were highly resistant to
VCR (LC50=41.0jigml-') and DNR (LC50=0.9 11gml-')
did not accumulate less VCR or DNR than cells from nine
other cases. Also, in this case, DNR- and VCR accumulation
and -cytotoxicity were not influenced by resistance modifiers.
Discussion
Although chemotherapeutic regimens have dramatically im-
proved the overall prognosis in childhood ALL the prognosis
for those with relapsed ALL is still poor. Cellular drug
resistance is most probably one of the main factors responsi-
ble for this fact. However, the knowledge about mechanisms
and types of cellular drug resistance in childhood ALL is
very limited.
Weisenthal et al. (1986) found that relapsed ALL patients
were significantly more resistant to VCR, dexamethasone and
doxorubicin but not to Must. For Ara-C the results depen-
ded on the concentration tested. In the present study we
showed that a group of 11 children with relapsed ALL was
significantly more resistant to DNR, 6-TG, Ara-C, alkylating
drugs and Pred, but not to VCR and L-Asp than a group of
41 children with ALL at initial diagnosis. This suggests that
L-Asp and VCR are not involved very often in drug resis-
tance in children with relapsed ALL.
In both Weisenthal's study and the present study there
were large overlaps in the ranges of LCso values of untreated
and relapsed patients. When we evaluated the drug resistance
profiles of individual children with relapsed ALL, large
interindividual differences in the patterns of drug resistance
and the degree of resistance were found. In some patients a
general drug resistance was found while others were in vitro
resistant to only one to three out of eight tested drugs. This
might illustrate the fact that resistance of leukaemic cells to
anticancer drugs is only one of the factors contributing to the
poor prognosis in relapsed leukaemia. Interpatient phar-
macokinetic variabilities are clearly related to the probability
of oncolytic effects (Evans et al., 1989). On the other hand,
the large interindividual differences in drug resistance profiles
suggest that for some patients combinations of effective
antileukaemic drugs might be composed while this is not
possible for those with a general resistance. Prevention of
unnecessary toxicity caused by drugs to which the leukaemic
cells are resistant is another goal to achieve. Larger studies
might be very useful in designing new treatment protocols for
the poor risk groups and perhaps even in tailoring chemo-
therapy for individual poor risk patients. The first data of a
very recently published non-randomised study of Hongo et
al. (1990) have to be handled with care but are encouraging:
Eleven courses of chemotherapy based on the data of the
MTT assay in children with relapsed leukaemia resulted in a
response in nine cases compared to only six responses in 15
courses not based on the MTT assay.
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In the last few years much attention has been paid to the
MDR model. Several aspects of this model can be distin-
guished:
(a) cross resistance to specific classes of drugs like vinca-
alkaloids and anthracyclines, but not to other drugs for
instance antimetabolites and Pred.
(b) a decreased drug accumulation, caused by
(c) the expression of P-gp on the cell membrane, and
(d) reversal of the resistance by resistance modifiers like
CsA and Vp. However, clinical drug resistance is not always
the result of MDR. Resistance to vinca-alkaloids and anthra-
cyclines not related to P-gp mediated MDR, can occur.
Haber et al. (1989) described a leukaemic cell line that was
resistant to VCR not because of in vitro exposure to drugs
VCR _ VCR + CsA,
Vp, or Lid
> _DNR _DNR + CsA,
.E Vp, or Lid
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Figure 3 LCS values of cells treated with cytostatic drug with
and without the addition of the resistance modifiers Lid =-
lidocaine, Vp = verapamil, and CsA = cyclosporine A. The LCS
values of the combination of cytostatic drugs with resistance
modifiers are corrected for the effect of resistance modifier alone.
For each patient the drug concentration is chosen that results in
a LCS between 50 and 100%. If this LCS value was not
evaluable the LCS closest to 50% was chosen. This was done to
avoid false negative effects of a resistance modifier because the
concentration of cytostatic drug could be too low to kill leu-
kaemic cells or because a too high concentration of the cytostatic
drug already killed almost all cells so that no enhancing effect of
a modifier can be detected.
but because of chemotherapy administered to the patient.
This VCR resistance was not due to the classic MDR model.
In their study only one cell line from a single patient was
analysed. Studies of fresh tumour samples from patients are
scarce. In the present study we analysed the drug resistance
profile of 11 patients with relapsed ALL compared to a large
group of untreated ALL patients. Cells from relapsed pa-
tients were more resistant to DNR but not to VCR. In four
relapsed patients a DNR resistance was present that was
associated with VCR resistance in only two cases. In all cases
a resistance to drugs not involved in MDR was also found.
P-gp expression was not found in these DNR- or VCR-
resistant cases, in ten other relapsed nor in 28 untreated ALL
patients. This is in accordance with three recent studies that
made clear that P-gp is infrequently found in childhood
initial and relapsed ALL (Tawa et al., 1990; Rothenberg et
al., 1989; Ubezio et al., 1989). In other types of leukaemia it
probably plays a more important role in clinical drug resis-
tance (Mattern et al., 1989; Ma et al., 1987; Carulli et al.,
1988; Sugawara et al., 1989).
Resistance modifiers did not enhance the cytotoxic effect
against cells from children with relapsed ALL patients. These
cells were significantly resistant to DNR but not to VCR. In
Weisenthal's study (1987) in which cells from relapsed ALL
patients were more in vitro resistant to VCR than cells from
untreated' patients, resistance modifiers potentiated VCR
effect in five out of eight relapsed and in 0 out of four
untreated ALL samples. This earlier study and the present
study show differences in methods which might have con-
tributed to the apparent disparity in findings: The number of
relapsed patients in the present study is lower, i.e. 11 vs 27 in
the previous study. However, more recently we have tested 29
relapsed ALL samples and over 100 untreated ALL samples
and no significant differences were found for VCR nor for
vindesine (Klumper et al., 1991). Our samples were cryo-
preserved and the endpoint was the LC50 instead of cell kill
at a single drug concentration. Also, the concentrations of
modifiers were different and in the previous study the
leukaemic cells were pre-incubated with modifiers for one
hour. Finally, it might be that children from the previous
study have been more heavily pretreated with VCR.
In two studies of adult ANLL in which MDR probably
plays an important role, the effect of verapamil on uptake
and cytotoxicity of anthracyclines was higher in cells from
patients resistant to clinical chemotherapy (Maruyama et al.,
1989; Tidefelt et al., 1988). In our study resistance modifiers
did not increase the accumulation and cytotoxicity of DNR
and VCR in cells from R3, the relapsed case most resistant
to VCR and DNR. Also, these cells did not accumulate less
VCR and DNR than cells from other patients.
Altogether, these findings indicate that DNR- and VCR
resistance in children with relapsed ALL is not due to the
mechanism of classic MDR. However, these conclusions are
generalisations from a small study which may not apply to
all individual ALL patients. Resistance to VCR and DNR is
most often due to other still unknown mechanisms. This is in
accordance with the finding that decreased uptake and reten-
Table IV Accumulation of0.5tLM vincristine (VCR) and 0.5 sM daunorubicin (DNR) with and without
8 ILM verapamil (Vp) by ALL cells. Untr = untreated. VCR and DNR accumulation are given as pmol/106
cells and corrected for cell size as pmol/ftm2 cell area.
Case DNRP DNR + Vpa (%) VCRa VCR + Vpa (%) Areab DNR VCRc
R3b 54.6 54.6 (100) 1.64 1.75 (107) 141 38.7 1.16
RII 0.54 0.59 (109) 65 0.83
R12 69.2 69.9 (101) 1.14 1.68 (147) 128 54.1 0.89
Untr ALL 59.7 54.8 (92) 1.17 1.55 (132) 123 48.5 0.95
Untr ALL 1.28 1.37 (107) 73 75.3 1.75
Untr ALL 0.48 0.39 (81) 81 0.59
Untr ALL 27.2 24.8 (91) 0.62 1.04 (168) 102 26.7 0.61
Untr ALL 0.90 1.15 (128) 75 1.20
Untr ALL 44.0 36.5 (83) 1.35 1.80 (133)
Untr ALL 16.8 16.8 (100) 0.45 0.65 (144) 114 14.7 0.39
apmol/106 cells. bAm2. Cpmol/lIm2696 R. PIETERS et al.
tion of vinca-alkaloids and anthracyclines are not the only
factors accounting for resistance to these classes of drugs
(Ubezio et al., 1989; Rivera-Fillat et al., 1988). Diversion to
some cellular compartment might play a role. Changes in
topoisomerases or disturbed intracellular drug distributions
are other possible explanations.
A remarkable phenomen was that CsA enhanced leu-
kaemic cell survival in two cases. This has been observed
earlier in tumour cell lines (Schuurhuis et al., 1990) and
might be a warning against the use of CsA in clinical trials
on reversal of drug resistance.
We conclude that children with relapsed ALL show vary-
ing types of drug resistance. Notwithstanding the fact that
large interindividual differences exist in degree of resistance
and number of drugs to which a resistance is detected,
significant differences between relapsed and untreated
patients were found in sensitivity to DNR, 6-TG, Pred,
Ara-C and alkylating drugs but not in sensitivity to VCR
and L-Asp. DNR- and VCR resistance in childhood relapsed
ALL is not due to P-gp mediated MDR which is not an
important mechanism of drug resistance in these patients.
Future studies on clinical drug resistance in ALL should not
only focus on P-gp expression but should incorporate data of
in vitro drug sensitivity testing because this measures the end
result of all mechanisms of drug resistance. The acquired
knowledge of resistance could lead to improved therapies for
children with relapsed ALL.
This study was supported by the Dutch Cancer Society (IKA
87-17). We thank Dr P.J. van Diest and Prof J.P.A. Baak for their
help in cytomorphometric analysis.
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